Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pt(iv) antitumor prodrugs: dogmas, paradigms, and realities
Mauro Ravera, Elisabetta Gabano, Michael J. McGlinchey, et al.
Dalton Transactions (2021) Vol. 51, Iss. 6, pp. 2121-2134
Closed Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

New anti-cancer explorations based on metal ions
Han Hu, Qi Xu, Zhimin Mo, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 66
Oxaliplatin and its derivatives – An overview
Paul O'Dowd, Darragh F. Sutcliffe, Darren M. Griffith
Coordination Chemistry Reviews (2023) Vol. 497, pp. 215439-215439
Open Access | Times Cited: 33
Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands
Zhiqin Deng, Guangyu Zhu
Current Opinion in Chemical Biology (2023) Vol. 74, pp. 102303-102303
Closed Access | Times Cited: 31
Platinum-based drugs in cancer treatment: Expanding horizons and overcoming resistance
Mona Shahlaei, Shaahin Mohammadzadeh Asl, Atefe Derakhshani, et al.
Journal of Molecular Structure (2023) Vol. 1301, pp. 137366-137366
Closed Access | Times Cited: 23
Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy
Yu Lu, Di Zhu, Quynh Chi Le, et al.
Nanoscale (2022) Vol. 14, Iss. 44, pp. 16339-16375
Open Access | Times Cited: 32
Platinum(IV) and platinum(II) anticancer complexes with biologically active releasable ligands
Pavel Štarha, Radka Křikavová
Coordination Chemistry Reviews (2023) Vol. 501, pp. 215578-215578
Closed Access | Times Cited: 21
Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups
Qiyuan Zhou, Shu Chen, Zoufeng Xu, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 18
Closed Access | Times Cited: 18
The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives
Giulia Coffetti, Martina Moraschi, Giorgio Facchetti, et al.
Molecules (2023) Vol. 28, Iss. 8, pp. 3407-3407
Open Access | Times Cited: 16
Pt(iv) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?
Alvaro Lopez-Sanchez, Hélène Bertrand
Inorganic Chemistry Frontiers (2024) Vol. 11, Iss. 6, pp. 1639-1667
Closed Access | Times Cited: 7
Disulfide-containing polymer delivery of C527 and a Platinum(IV) prodrug selectively inhibited protein ubiquitination and tumor growth on cisplatin resistant and patient-derived liver cancer models
Kun Shang, Lingpu Zhang, Yingjie Yu, et al.
Materials Today Bio (2023) Vol. 18, pp. 100548-100548
Open Access | Times Cited: 14
Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin‐Encapsulated Pt(IV) Nanodrug for the Treatment of Non‐Small Cell Lung Cancer
Huixiang Tian, Jie Mei, Lei Cao, et al.
Small (2023) Vol. 19, Iss. 49
Open Access | Times Cited: 14
Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties
Ling‐Wen Xu, Xiangyu Kong, Xinzhi Li, et al.
Molecules (2024) Vol. 29, Iss. 4, pp. 746-746
Open Access | Times Cited: 5
Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38/MAPK and MDR pathways for cancer chemo-immunotherapy
Xiaomeng Liu, Zhe Li, Xiaoya Wang, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 797-813
Closed Access
Multi-specific niflumic acid platinum(iv) complexes displaying potent antitumor activities by improving immunity and suppressing angiogenesis besides causing DNA damage
Linming Li, Ming Zhang, Dianlong Jia, et al.
Dalton Transactions (2022) Vol. 52, Iss. 1, pp. 147-158
Closed Access | Times Cited: 19
Platinum(IV) Derivatives of [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)] with Diclofenac Ligands in the Axial Positions: A New Class of Potent Multi-action Agents Exhibiting Selectivity to Cancer Cells
Hana Kostrhunová, Brondwyn S. McGhie, Lenka Marková, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 7894-7908
Open Access | Times Cited: 12
Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
Jingjing Huang, Ding Wei-ze, Xingfan Zhu, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 16
The current status in computational exploration of Pt(iv) prodrug activation by reduction
Fortuna Ponte, Stefano Scoditti, Gloria Mazzone, et al.
Physical Chemistry Chemical Physics (2023) Vol. 25, Iss. 23, pp. 15586-15599
Open Access | Times Cited: 10
Potent Chlorambucil-Platinum(IV) Prodrugs
Angelico D. Aputen, Maria George Elias, Jayne Gilbert, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10471-10471
Open Access | Times Cited: 15
Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups
Qiyuan Zhou, Shu Chen, Zoufeng Xu, et al.
Angewandte Chemie (2023) Vol. 135, Iss. 18
Closed Access | Times Cited: 7
Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines
Marie‐Christin Barth, Norman Häfner, Ingo B. Runnebaum, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5718-5718
Open Access | Times Cited: 7
Polysaccharide‑platinum complexes for cancer theranostics
Yunxia Yang, Pengge Wang, Zengrui Ji, et al.
Carbohydrate Polymers (2023) Vol. 315, pp. 120997-120997
Closed Access | Times Cited: 7
Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity
Angelico D. Aputen, Maria George Elias, Jayne Gilbert, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2181-2181
Open Access | Times Cited: 2
Oxoplatin‐Based Pt(IV) Lipoate Complexes and Their Biological Activity
Xiao Liu, Marie‐Christin Barth, Klaudia Cseh, et al.
Chemistry & Biodiversity (2022) Vol. 19, Iss. 10
Open Access | Times Cited: 11
Multi-action platinum(IV) prodrugs conjugated with COX-inhibiting NSAIDs
Xiao Liu, Dominik Wenisch, Philipp Dahlke, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115515-115515
Open Access | Times Cited: 6
Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates
Angelico D. Aputen, Maria George Elias, Jayne Gilbert, et al.
Molecules (2022) Vol. 27, Iss. 20, pp. 7120-7120
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top